Moderna, Inc. (MRNA)
MRNA Advances Cancer Pipeline With New Immunotherapy Study
Moderna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to report second quarter results on July 31, with investors focused on the impact of seasonal COVID-19 vaccine demand and updates on the company's late-stage pipeline, including anticipated Phase III melanoma data. Jefferies analysts expect a largely uneventful earnings report after Moderna previously guided for second-quarter revenue of $50 million to $100 million, down from $389 million in the first quarter, reflecting the seasonal nature of COVID vaccine sales.
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
Moderna (MRNA) reached $66.98 at the closing of the latest trading day, reflecting a -1.89% change compared to its last close.
Arbutus Biopharma: Moderna Validates My IP Bull Case
Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patents. As for ABUS' in-house assets, I think Imdusiran has shown durable viral control. The main caveat is that it comes from combo therapies. Their balance sheet gives them a comfortable runway to pursue imdusiran's upcoming Phase 2b trial, which is yet another optionality vertical for the stock.
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
Moderna wins EU contract for RSV vaccine supply
Moderna said on Thursday it has secured a European Commission contract to supply its respiratory syncytial virus vaccine to six countries in the region.
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
Moderna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.
Short Squeeze Alert—Moderna Stock Surges on New Strategy
At that time, Moderna revealed its strategy for using mRNA to combat cancer and rare diseases. It's a move beyond vaccines, and investors seem to like it.
MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines
Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.
Moderna stock soars as cancer pipeline and CAR-T push ignite optimism
Moderna Inc. (MRNA) shares surged nearly 10% on Friday, extending a powerful rally that has lifted the stock about 40% over the past month and significantly outperformed the broader market. The gains followed the company's Science Day presentation and investor event, where Moderna outlined an ambitious strategy to expand beyond its COVID-19 vaccine business and build a diversified portfolio spanning oncology, autoimmune diseases, and next-generation mRNA therapies.
Moderna Is Up 13% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer.
Why Moderna Stock Is Soaring and Leading the S&P 500 Today
Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.
